UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000022266 |
|---|---|
| Receipt number | R000025653 |
| Scientific Title | The Influence on SPecific Activity of protein S and coagulation system : Dienogest and low dose estrogen-progestin for Endometriosis. |
| Date of disclosure of the study information | 2016/05/10 |
| Last modified on | 2020/05/13 10:20:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Influence on SPecific Activity of protein S and coagulation system :
Dienogest and low dose estrogen-progestin for Endometriosis.
Acronym
The Influence on SPecific Activity of protein S and coagulation system :
Dienogest and low dose estrogen-progestin for Endometriosis. (SPADE)
Scientific Title
The Influence on SPecific Activity of protein S and coagulation system :
Dienogest and low dose estrogen-progestin for Endometriosis.
Scientific Title:Acronym
The Influence on SPecific Activity of protein S and coagulation system :
Dienogest and low dose estrogen-progestin for Endometriosis. (SPADE)
Region
| Japan |
Condition
Condition
Endometriosis
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To clarify an influence of dienogest and low dose estrogen-progestin for endometriosis on protein S- specific activity.
Basic objectives2
Others
Basic objectives -Others
Change of protein S-specific activity (total activity, total antigen level and those ratios)
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Change of protein S specific activity (total activity, total antigen level and those ratios)
Key secondary outcomes
Effect of dienogest and low dose estrogen-progestin on the parameters of coagulation system (excluding protein S specific activity), incidence of venous thromboembolism, incidence ratios of adverse event (including the abnormal change of laboratory test to be clinically problem).
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Other |
Interventions/Control_1
The laboratory tests are carried out at 4 times before and during treatment period.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 50 | years-old | > |
Gender
Female
Key inclusion criteria
1. Patients with treatment start plan of dienogest or low dose estrogen-progestin for endometriosis.
2. Female patients with more than 20 years and less than 50 years at the date of informed consent.
3. Patients with menstrual cycle.
4. Patients providing the written informed consent.
Key exclusion criteria
1. Patients with pregnant or the possibility of pregnancy.
2. Patients with post partum within 4 weeks or with lactation.
3. Patients with abnormal genital bleeding not to be diagnosed.
4. Patients with the complication of malignant tumor or the suspicion of complication.
5. Patients with severe hepatic disorder or hepatic tumor.
6. Patients within 4 weeks after the operation (excluding operational duration of less than 30 min).
7. Patients without continuous administration for 24 weeks.
8. Patients with treatment history of steroidal hormones including sex hormones and GnRH agonist within the past 3 months.
9. Patients under anticoagulation and antiplatelet drug.
10. Patients with hypersensitivity to the constituents of the study drug (dienogest tablets or low dose estrogen-progestin tablets).
11. Patients with contraindication of Lunabell tablet LD/ULD and Yaz tablet in low dose estrogen-progestin group.
12. Patient who is judged to be inappropriate for study participation for any reason by the doctor.
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kiyoko Kato |
Organization
Kyushu University Hospital
Division name
Department of Obstetrics and Gynecology
Zip code
Address
3-1-1, Maidashi, Higashi-Ku, Fukuoka
TEL
092-642-5395
kkato@med.kyushu-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Natsuko Yokota |
Organization
Kyushu University Hospital
Division name
Department of Obstetrics and Gynecology
Zip code
Address
3-1-1, Maidashi, Higashi-Ku, Fukuoka
TEL
092-642-5395
Homepage URL
natsuko.yokota.192@s.kyushu-u.ac.jp
Sponsor or person
Institute
Department of Obstetrics and Gynecology, Kyushu University Hospital
Institute
Department
Personal name
Funding Source
Organization
Clinical Research Support Center Kyushu
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
JAPAN
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
九州大学病院（福岡県）、長崎国際大学（長崎県）、国家公務員共済組合連合会 浜の町病院（福岡県）、医療法人 親愛ステーションクリニック（福岡県）、医療法人 中央レディスクリニック（福岡県）、北九州市立医療センター（福岡県）、独立行政法人地域医療機能推進機構JCHO九州病院（福岡県）、済生会支部福岡県 済生会福岡総合病院（福岡県）、日本赤十字社 福岡赤十字病院（福岡県）、医療法人社団 高邦会 福岡山王病院（福岡県）、医療法人社団 水光会 宗像水光会総合病院（福岡県）、国立病院機構福岡東医療センター（福岡県）、順天堂大学医学部附属順天堂医院（東京都）、公益財団法人東京都保険医療公社 東部地域病院（東京都）、越谷市立病院（埼玉県）
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 05 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 04 | Month | 25 | Day |
Date of IRB
| 2016 | Year | 05 | Month | 12 | Day |
Anticipated trial start date
| 2016 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2019 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
| 2019 | Year | 08 | Month | 27 | Day |
Date analysis concluded
| 2019 | Year | 12 | Month | 23 | Day |
Other
Other related information
Prospective cohort study
Dienogest group and low dose estrogen-progestin group patients who take hormonal treatment for endometriosis from May X,2016 to September 30,2017 and meet inclusion criteria.
Clinical examination
Protein S-specific activity,Protein S activity,Protein C activity,PT,APTT,D-dimer,fibrinogen,Thrombin-antithrombin complex,estradiol,progesteron
Management information
Registered date
| 2016 | Year | 05 | Month | 10 | Day |
Last modified on
| 2020 | Year | 05 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025653
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
